[pubmed] Risk of non-infectious uveitis or myasthenia gravis in patients on checkpoint inhibitors in a large healthcare
Posté : 22 oct. 2020 12:00
Br J Ophthalmol. 2020 Oct 21:bjophthalmol-2020-317060. doi: 10.1136/bjophthalmol-2020-317060. Online ahead of print.
ABSTRACT
AIM: To determine if checkpoint inhibitors (CPIs) confer an increased risk of non-infectious uveitis or myasthenia gravis (MG) compared to patients on non-checkpoint inhibitor (N-CPI) chemotherapy.
METHODS: A retrospective cohort study was performed comparing patients in a large commercial and Medicare advantage database exposed to CPI compared to N-CPI. All patients who initiated a CPI (ipilimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, cemiplimab and durvalumab) were eligible. Date of earliest CPI in the exposure group and N-CPI chemotherapy in the comparator group was considered the index date. Exclusion occurred in both cohorts for any history of uveitis or MG diagnosis and having
Source: https://pubmed.ncbi.nlm.nih.gov/3308731 ... 8&v=2.12.6